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ABSTRACT 
There is limited data on the effectiveness of Dolutegravir (DTG) based combination 
antiretroviral therapy (ART) in real life settings in southern Africa where HIV-1C predominates. 
We report here a patient infected with HIV-1C on DTG based ART previously exposed to 
raltegravir who developed multidrug resistance mutations to four ARV classes. There is need for 
drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment 
programmes even in the era of DTG based ART. 
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INTRODUCTION 
Maintaining viral load (VL) suppression in people living with HIV (PLWHIV) is critical to 
ensure both the health of PLWHIV, and prevent onward transmission of HIV to sexual partners 
[1–3]. Despite major advances in the development of antiretroviral (ARV) drugs and 
antiretroviral therapy (ART) treatment guidelines [4–6], low and middle income countries 
(LMICs) continue to face challenges such as poor ART adherence,  limited HIV care specialists, 
drug stock-outs, lack of ancillary health care services, etc [7–9]. These barriers to effective ART 
may lead to development of extensive HIV-1 drug resistance.  
Dolutegravir (DTG) has recently been introduced as part of the first-line ART regimen in 
Botswana, and may soon be adopted by other countries in sub-Saharan Africa (SSA) [10],[11]. 
Therefore, there is a need to monitor the development of integrase strand transfer inhibitor 
(INSTI) resistance mutations. We report a case of a four-class drug resistant HIV-1 subtype C in 
a 51-year-old male currently on DTG-based ART with persistent viremia. 
 
METHODS 
Chart reviews of treatment-experienced patients not virologically suppressed while on salvage 
ART therapy were conducted at a local tertiary hospital as part of the Botswana Epidemiological 
ART Treatment (BEAT) cohort study. A case-file reported herein was identified and an analysis 
of the patient’s medical record was conducted with information gathered from September 2003 
to November 2017. The patient provided written informed consent to complete the analysis for 
publication, and the BEAT Study is approved by the human research and development council of 
Botswana. 
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Genotypic resistance testing (GRT) was performed using Sanger sequencing of the pol and 
envelope genes. Sequences obtained were assessed for drug resistance mutations using the 
Stanford University HIV drug resistance database (https://hivdb.stanford.edu/), International 
Antiviral Society USA (IAS-USA) 2017 mutational list [12] and coreceptor usage was 
determined using with geno2pheno[coreceptor] [13]. All sequences generated were submitted to 
GenBank under accession numbers MG989439 - MG989443, MH004049 and MH004050. 
 
RESULTS AND DISCUSSION 
Case Report 
This patient was initiated on zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP) on 
September 2003 as per the 2002 Botswana National ART guidelines. Apart from persistent 
viremias, his 14-year follow-up history has been clinically uneventful and devoid of 
opportunistic infections.  
He intermittently achieved virological suppression between September 2003 to April 2014 (6 
HIV-1 RNA levels <400 copies/ml out of 67 tests) (Figure 1). His ART regimens while 
virologically suppressed were AZT / tenofovir (TDF) / ritonavir-boosted lopinavir (LPV\r) from 
April 2007 and TDF / emtricitabine (FTC) / ritonavir-boosted darunavir (DRV\r) / raltegravir 
(RAL) for the remaining aviremic episodes from February 2010. The majority of VL revealed 
virological failure (VF) with VL ranging between 2.61 log10 and 5.88 log10 copies/ml (Figure 1). 
Nine switches in ARV medications were made from September 2003 to November 2017 (Figure 
1). Adherence to clinic appointments and medications was suboptimal and he experienced one 
episode of drug stock-out of ARVs (darunavir) for approximately 2 weeks in March 2012. His 
social circumstances remained challenging, making it difficult for him to be adherent to his 
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medications despite multiple counseling and adherence support sessions from health care 
providers.   
The patient is infected with HIV-1C clade and during the period under review had a median 
HIV-1 VL of 3.48 log10 (IQR: 3.27-3.68) copies/mL and absolute CD4+T cell count of 595 
cells/µL (IQR: 501-692) respectively. As of November 2017, VL and CD4+T cell count were 
3.57 log10 cps/mL and 670 cells/µL respectively (Figure 1). 
Resistance Testing 
GRT analysis revealed major drug resistance mutations conferring resistance to:  nucleoside 
(nucleotide) reverse transcriptase inhibitors [N (t) RTIs] (K65R, D67N, K70R, M184V and 
K219N), non-nucleotide reverse-transcriptase inhibitors (NNRTIs) (Y181C), protease inhibitors 
(PIs) (V32I, I47V, 154L, I84V) and INSTIs (E138K, G140A, S147G, Q148R, T97A). The virus 
was chemokine receptor 5 (CCR5) tropic and did not have any resistance mutations to 
enfuvirtide (T-20).  
To our knowledge, this is the first report in SSA of a patient with a virus which has developed 
drug resistance mutations to all the standard ARVs belonging to four classes including INSTIs. 
Multidrug resistant mutations likely developed as a result of multiple factors including, 
suboptimal adherence, inadequate psychosocial support and limited HIV specialist care – all 
issues encountered frequently in LMICs. 
While invitro and invivo clinical studies have shown DTG to retain some activity against a virus 
with INSTI mutations [14],[15], this is not always the case in real-life settings as highlighted by 
this case report. An interesting observation made was the isolated emergence of the INSTI 
accessory resistance mutation T97A between May 2015 and November 2017 and concurrent rise 
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in VL from 2,888cps/mL to 3,690 cps/mL between the same time period. Similar observations of 
viral rebound after sole emergence of T97A mutations have recently been reported [16]. 
Phenotypic testing, ARV drug tracing levels and directly observed therapy would have been 
ideal but often these are not available or feasible in LMICS. 
This patient may benefit from a regimen that includes two new agents expected to be fully 
active, such as maraviroc (MVC) or enfuvirtide (T-20) with an optimized background regimen. 
Currently, MVC and T-20 are not available under the Botswana National HIV Clinical Care 
Guidelines.  
As this patient remains sexually active with significant psychosocial issues, this raises important 
public health issues including the possible introduction of a multidrug resistant HIV-1C strain 
into the circulating pool.  
 
CONCLUSIONS      
 
The case highlights the need for continued monitoring of HIV-1 VL and the development of 
robust HIV drug resistance surveillance systems for failing and highly treatment-experienced 
patients. Managing treatment-experienced patients in LMICs, where there is often inadequate 
psychosocial support, lack of clinical HIV care expertise, limited ARV options and drug 
resistance testing capacity, will remain an ongoing challenge that will need to become a public 
health priority to ensure the effectiveness of national HIV programmes. 
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Figure 1.  Plasma Viral Loads, CD4+T cell count and HAART regimens at different time 
points over a 14 year period for the patient. 
(Source: modified version from; 
http://bioafrica.mrc.ac.za/workshops/PDFs/deOliveiraRegaDB.pdf) 
Horizontal line within chart depicts VL of 400copies/ml.  
Numbered rectangular callouts depict when drug resistance testing was done 
1. Mar-2009; †NRTIs, D67N, K70R, M184V; NNRTIs, Y181C; PIs Major R.M, V32I, I47V, 
I54L, I84V, †PIs Accessory R.M, L33F, G73V, L89T; INSTIs, Not tested 
2. Apr-2009; † NRTIs, D67N, K70R, M184V, K219N; †NNRTIs, Y181C; †PIs Major R.M, 
V32I, I47V, I54L, I84V, PIs Accessory R.M, L33F, G73V, L89T; INSTIs, Not tested 
3. May-2015; †NRTIs, K65KR, D67DN, K70KR, M184MV, K219KHNQ; †NNRTIs None; 
†PIs Major R.M, V32VI, I54IL, I84IV, †PIs Accessory R.M, L33LF, G73GV, L89IMT; 
†INSTIs Major R.M, E138K, G140A, Q148R, INSTIs Accessory R.M, None; 
4. Aug-2016; †NRTIs, D67N, K70R, M184V; † NNRTIs, None; †PIs Major R.M, V32I, I47V, 
I54L, I84V, †PIs Accessory R.M, L33F, G73V, L89T; INSTIs, Not tested. 
5. Nov-2017; † INSTIs Major R.M, E138K, G140A, S147G, Q148R, INSTIs Accessory R.M, 
T97A; ‡FIs, none; EIs, §R5 Tropic; NRTIs, Not tested; NNRTIs, Not tested. 
NRTIs, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTIs, non nucleotide reverse 
transcriptase inhibitors; PIs, protease inhibitors; INSTIs, integrase strand transfer inhibitors; RM, 
Resistance Mutations; FIs, Fusion Inhibitors; EIs, entry inhibitors; AZT, zidovudine;3TC, 
lamivudine; NVP, nevirapine; d4T, didanosine; ddI, didanosine; NFV, nelfinavir; TDF, 
tenofovir; LPV/r, ritonovir boosted lopinavir; ABC, abacavir; FTC, emtricitabine; SQV/r, 
ritonivir boosted saquinavir; DRV/r, ritonivir boosted darunavir; RAL, raltegravir; DTG, 
dolutegravir; VF, virological failure 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
 
 
Drug resistance mutations interpreted using; 
 †, Stanford University HIV Drug resistance database; ‡, International Antiviral Society USA 
(IAS-USA) 2017 mutational list; §, co-receptor usage assessed with geno2pheno [coreceptor]. 
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